APA (7th ed.) Citation

K, Y., S, K., M, K., M, H., Y, S., T, H., . . . N, M. (2026). The impact of NK1 receptor antagonist selection on chemotherapy-related adverse events: A retrospective study of adverse events in paclitaxel or nab-paclitaxel and carboplatin combination therapy with fosnetupitant and aprepitant use. Frontiers in pharmacology, 17, 1712949. https://doi.org/10.3389/fphar.2026.1712949

Chicago Style (17th ed.) Citation

K, Yamaoka, Kajita S, Kume M, Hirabatake M, Sato Y, Hashida T, Tachikawa R, and Muroi N. "The Impact of NK1 Receptor Antagonist Selection on Chemotherapy-related Adverse Events: A Retrospective Study of Adverse Events in Paclitaxel or Nab-paclitaxel and Carboplatin Combination Therapy with Fosnetupitant and Aprepitant Use." Frontiers in Pharmacology 17 (2026): 1712949. https://doi.org/10.3389/fphar.2026.1712949.

MLA (9th ed.) Citation

K, Yamaoka, et al. "The Impact of NK1 Receptor Antagonist Selection on Chemotherapy-related Adverse Events: A Retrospective Study of Adverse Events in Paclitaxel or Nab-paclitaxel and Carboplatin Combination Therapy with Fosnetupitant and Aprepitant Use." Frontiers in Pharmacology, vol. 17, 2026, p. 1712949, https://doi.org/10.3389/fphar.2026.1712949.